ASCEND: a Randomised, Double-Blinded, Placebo-Controlled, Phase II Study of Gemcitabine and Nab-Paclitaxel with LSTA1 in Untreated Metastatic Pancreatic Adenocarcinoma. an Australasian Gastro-Intestinal Trials Group (AGITG) Trial

J. Lee,A. Dean,T. Price,K. Sjoquist,V. Gebski, J. Mumford,F. Day,S. Yip,K. Wilson,C. Jackson, S. Padinharakam,B. Lee,M. Burge,D. Siu,C. Karapetis,L. Chantrill,Z.W. Wong,R. Jennens, C. Lomma, A. Franscesconi

ESMO Gastrointestinal Oncology（2023）

引用 0|浏览2

暂无评分

摘要

•First phase II trial combining iRGD with combination chemotherapy in PDAC.•First trial evaluating the combination of chemotherapy with a second dose of iRGD.•This trial will assess the feasibility of using ePROs in trial design.

查看译文

关键词

iRGD,pancreatic ductal adenocarcinoma,pancreatic carcinoma,LSTA1,chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要